the alcholics trial, page-21

Honestly,
If Bill Williams took the time to research SLA properly then he would know that the company have previously discussed the significance of the alcohol and drug trials in public, and in some detail. At the EGM Dr Nina Golovkina, who is the head of the department of Psychosomatic disorders at the Skvortsova-Stepanova Psychiatric Hospital, spoke in depth about these trials and how, for example, people in the trial who could previously not stand up, were able to walk unasisted within a week. This is something they had never seen before. In response to a question from a shareholder which was "Will your hospital use this substance to treat alcoholics and drug addicts?" she answered that the senior psychiatrists and neurologists at the hospital had met and determined that Ropren would be incorporated into the treatment of all drug induced psychosis as soon as it was available. A letter to that effect was sent by the head of the hospital, Dr Vladimir Agishev, to Solagran confirming this and that letter has been released to the market in an announcement.

In relation to "P values", a poster presented at the Rio Nevada conference by Con Stough, in relations to the Swinburne trials, had P values presented and they were all P <= 0.05. Anyway I'm sure more data will be released in due course when the company feels that it is appropriate.

Regards
Aksier